Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Bladder Cancer, May 2019

Free Subscription


Abstracts

Retrieve all available abstracts of the following 140 articles:
HTML format


 

Single Articles

  1. CRONISE KE, Hernandez BG, Gustafson DL, Duval DL, et al
    Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer.
    Mol Pharmacol. 2019 May 2. pii: mol.119.115808. doi: 10.1124/mol.119.115808.
    Abstract    

    Abstract available

  2. LI Y, Tindle HA, Hendryx MS, Xun P, et al
    Smoking Cessation and the Risk of Bladder Cancer among Postmenopausal Women.
    Cancer Prev Res (Phila). 2019;12:305-314.
    Abstract    

    Abstract available

  3. XIAN-LI T, Hong L, Hong Z, Yuan L, et al
    Higher Expression of Linc00152 Promotes Bladder Cancer Proliferation and Metastasis by Activating the Wnt/beta-Catenin Signaling Pathway.
    Med Sci Monit. 2019;25:3221-3230.
    Abstract    

    Abstract available

  4. YANG Y, Cheng Z, Jia X, Shi N, et al
    Mortality trends of bladder cancer in China from 1991 to 2015: an age-period-cohort analysis.
    Cancer Manag Res. 2019;11:3043-3051.
    Abstract    

    Abstract available

  5. ZHANG C, Wang W, Lin J, Xiao J, et al
    lncRNA CCAT1 promotes bladder cancer cell proliferation, migration and invasion.
    Int Braz J Urol. 2019;45.
    Abstract    

    Abstract available

  6. LEKO V, McDuffie LA, Zheng Z, Gartner JJ, et al
    Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder Cancer.
    J Immunol. 2019 Apr 29. pii: jimmunol.1801022. doi: 10.4049/jimmunol.1801022.
    Abstract    

    Abstract available

  7. KIM S, Kim Y, Kong J, Kim E, et al
    Epigenetic regulation of mammalian Hedgehog signaling to the stroma determines the molecular subtype of bladder cancer.
    Elife. 2019;8.
    Abstract    

    Abstract available


  8. Erratum to "Re: Elevated Bladder Cancer in Northern New England: The Role of Drinking Water and Arsenic".
    J Natl Cancer Inst. 2019 Apr 29. pii: 5481408. doi: 10.1093.
    Abstract    



  9. HECK CL, Schwartzbauer GT
    BCG-induced discitis and osteomyelitis in a patient with a history of bladder cancer.
    JAAPA. 2019;32:1-4.
    Abstract    

    Abstract available

  10. HEYES SM, Prior KN, Whitehead D, Bond MJ, et al
    Toward an Understanding of Patients' and Their Partners' Experiences of Bladder Cancer.
    Cancer Nurs. 2019 Apr 25. doi: 10.1097/NCC.0000000000000718.
    Abstract    

    Abstract available

  11. FAN L, Wang Y, Wang W, Wei X, et al
    Carcinogenic role of K-Ras-ERK1/2 signaling in bladder cancer via inhibition of H1.2 phosphorylation at T146.
    J Cell Physiol. 2019 Apr 29. doi: 10.1002/jcp.28716.
    Abstract    

    Abstract available

  12. CHEN W, Jiang T, Mao H, Gao R, et al
    Nodal Promotes the Migration and Invasion of Bladder Cancer Cells via Regulation of Snail.
    J Cancer. 2019;10:1511-1519.
    Abstract    

    Abstract available

  13. NAGAI T, Okamura T, Yanase T, Chaya R, et al
    Examination of Diagnostic Accuracy of UroVysion Fluorescence In Situ Hybridization for Bladder Cancer in a Single Community of Japanese Hospital Patients
    Asian Pac J Cancer Prev. 2019;20:1271-1273.
    Abstract    

    Abstract available

  14. RENNINGER M, Fahmy O, Schubert T, Schmid MA, et al
    The prognostic impact of hexaminolevulinate-based bladder tumor resection in patients with primary non-muscle invasive bladder cancer treated with radical cystectomy.
    World J Urol. 2019 Apr 27. pii: 10.1007/s00345-019-02780.
    Abstract    

    Abstract available

  15. NADAL R, Bellmunt J
    Management of metastatic bladder cancer.
    Cancer Treat Rev. 2019;76:10-21.
    Abstract    

    Abstract available

  16. PALMISANO F, Boeri L, Montanari E
    Reply letter to: Loh-Doyle JC, Ashrafi A, Nazemi A, et al. Dual Prosthetic Implantation After Radical Cystoprostatectomy and Neobladder: Outcomes of the Inflatable Penile Prosthesis and Artificial Urinary Sphincter in Bladder Cancer Survivors.
    J Sex Med. 2019;16:760-761.
    Abstract    



  17. GARCIA-PERDOMO HA, Usubillaga-Velasquez JP, Zapata-Copete JA, Reis LO, et al
    Mutations in CDKN2A and the FGFR3 genes on bladder cancer diagnosis: a systematic review and meta-analysis.
    World J Urol. 2019 Apr 27. pii: 10.1007/s00345-019-02779.
    Abstract    

    Abstract available

  18. STONE L
    Budding prognostic technique for muscle-invasive bladder cancer.
    Nat Rev Urol. 2019 Apr 26. pii: 10.1038/s41585-019-0187.
    Abstract    



  19. JHA S, Mitra S, Adhya AK, Nayak P, et al
    Urothelial carcinoma with villoglandular differentiation (UCVGD) with small cell neuroendocrine carcinoma of urinary bladder.
    BMJ Case Rep. 2019;12.
    Abstract    

    Abstract available

  20. NGWESO S, Mukhtar S, Forrest C, Mander J, et al
    Rare case of bladder chondroma causing lower urinary tract symptoms.
    BMJ Case Rep. 2019;12.
    Abstract    

    Abstract available

  21. LI G, Lei Q, Wang F, Deng D, et al
    Fluorinated Polymer Mediated Transmucosal Peptide Delivery for Intravesical Instillation Therapy of Bladder Cancer.
    Small. 2019 May 10:e1900936. doi: 10.1002/smll.201900936.
    Abstract    

    Abstract available

  22. NUMMI A, Jarvinen R, Sairanen J, Huotari K, et al
    A retrospective study on tolerability and complications of bacillus Calmette-Guerin (BCG) instillations for non-muscle-invasive bladder cancer.
    Scand J Urol. 2019 May 10:1-7. doi: 10.1080/21681805.2019.1609080.
    Abstract    

    Abstract available

  23. ZHUANG C, Huang X, Yu J, Gui Y, et al
    Circular RNA hsa_circ_0075828 promotes bladder cancer cell proliferation through activation of CREB1.
    BMB Rep. 2019 May 10. pii: 4552.
    Abstract    

    Abstract available

  24. ZHU J, Xu C, Ruan L, Wu J, et al
    MicroRNA-146b Overexpression Promotes Human Bladder Cancer Invasion via Enhancing ETS2-Mediated mmp2 mRNA Transcription.
    Mol Ther Nucleic Acids. 2019;16:531-542.
    Abstract    

    Abstract available

  25. SUN W, Li S, Yu Y, Jin H, et al
    MicroRNA-3648 Is Upregulated to Suppress TCF21, Resulting in Promotion of Invasion and Metastasis of Human Bladder Cancer.
    Mol Ther Nucleic Acids. 2019;16:519-530.
    Abstract    

    Abstract available

  26. CONG L, Yang Q, Hu C, Yu Q, et al
    Current Status of Functional Studies on Circular RNAs in Bladder Cancer and their Potential Role as Diagnostic and Prognostic Biomarkers: A Review.
    Med Sci Monit. 2019;25:3425-3434.
    Abstract    

    Abstract available

  27. ZHANG Z, Qin H, Jiang B, Chen W, et al
    miR-30e-5p suppresses cell proliferation and migration in bladder cancer through regulating metadherin.
    J Cell Biochem. 2019 May 8. doi: 10.1002/jcb.28866.
    Abstract    

    Abstract available

  28. BORCOMAN E, De La Rochere P, Richer W, Vacher S, et al
    Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer.
    Oncoimmunology. 2019;8:e1581556.
    Abstract    

    Abstract available

  29. ZHAOJIE L, Yuchen L, Miao C, Yacun C, et al
    Gelsolin-like actin-capping protein has prognostic value and promotes tumorigenesis and epithelial-mesenchymal transition via the Hippo signaling pathway in human bladder cancer.
    Ther Adv Med Oncol. 2019;11:1758835919841235.
    Abstract    

    Abstract available

  30. GUO CC, Majewski T, Zhang L, Yao H, et al
    Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer.
    Cell Rep. 2019;27:1781-1793.
    Abstract    

    Abstract available

  31. CLERIGO V, Castro A, Mourato T, Gomes C, et al
    A Rare Case of Granulomatous Pneumonitis Due to Intravesical BCG for Bladder Cancer.
    Acta Med Port. 2019;32:316-320.
    Abstract    

    Abstract available

  32. TSUJINO T, Sugito N, Taniguchi K, Honda R, et al
    MiR-143/MSI2/KRAS Cascade Contributes Positively to Carcinogenesis in Human Bladder Cancer.
    Cancer Sci. 2019 May 7. doi: 10.1111/cas.14035.
    Abstract    

    Abstract available

  33. ZHU W, Liu H, Wang X, Lu J, et al
    Long noncoding RNAs in bladder cancer prognosis: A meta-analysis.
    Pathol Res Pract. 2019 Apr 29:152429. doi: 10.1016/j.prp.2019.
    Abstract    

    Abstract available

  34. SORENBY A, Baseckas G, Bendahl PO, Brandstedt J, et al
    Reducing recurrence in non-muscle-invasive bladder cancer by systematically implementing guideline-based recommendations: effect of a prospective intervention in primary bladder cancer patients.
    Scand J Urol. 2019 May 8:1-7. doi: 10.1080/21681805.2019.1604568.
    Abstract    

    Abstract available

  35. KRISHNATREYA M
    Gall bladder cancer in Delhi - some thoughts.
    Indian J Cancer. 2019;56:182.
    Abstract    



  36. FARHOOD B, Raei B, Ameri H, Shirvani M, et al
    A review of incidence and mortality of colorectal, lung, liver, thyroid, and bladder cancers in Iran and compared to other countries.
    Contemp Oncol (Pozn). 2019;23:7-15.
    Abstract    

    Abstract available

  37. LYON TD, Frank I, Takahashi N, Boorjian SA, et al
    Sarcopenia and Response to Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2019 Mar 25. pii: S1558-7673(19)30102.
    Abstract    

    Abstract available

  38. HU X, Guo Z, Xu J, Mei X, et al
    Role of feline sarcomarelated protein in the viability and apoptosis of bladder cancer cells.
    Mol Med Rep. 2019 Apr 30. doi: 10.3892/mmr.2019.10204.
    Abstract    

    Abstract available

  39. BEN FRADJ MK, Mrad Dali K, Kallel A, Bibi M, et al
    Interaction Effects of Plasma Vitamins A, E, D, B9, and B12 and Tobacco Exposure in Urothelial Bladder Cancer: A Multifactor Dimensionality Reduction Analysis.
    Nutr Cancer. 2019 May 6:1-8. doi: 10.1080/01635581.2019.1609531.
    Abstract    

    Abstract available

  40. ABBAS W, Goel V, Verma A, Gupta VG, et al
    Harnessing the Immunomodulatory Effects of Radiation in Urinary Bladder Cancer.
    Cureus. 2019;11:e4108.
    Abstract    

    Abstract available

  41. ABDOLMALEKI F, Ghafoui-Fard S, Taheri M, Mordadi A, et al
    Expression analysis of a panel of long non-coding RNAs (lncRNAs) revealed their potential as diagnostic biomarkers in bladder cancer.
    Genomics. 2019 May 2. pii: S0888-7543(19)30012.
    Abstract    

    Abstract available

  42. MACLEOD LC, Yabes JG, Yu M, Fam MM, et al
    Trends and appropriateness of perioperative chemotherapy for muscle-invasive bladder cancer.
    Urol Oncol. 2019 Apr 30. pii: S1078-1439(19)30139.
    Abstract    

    Abstract available

  43. KRAFFT U, Tschirdewahn S, Hess J, Harke NN, et al
    Validation of survivin and HMGA2 as biomarkers for cisplatin resistance in bladder cancer.
    Urol Oncol. 2019 Apr 30. pii: S1078-1439(19)30148.
    Abstract    

    Abstract available

  44. RUI X, Gu TT, Pan HF, Zhang HZ, et al
    Evaluation of PD-L1 biomarker for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatments for urothelial carcinoma patients: A meta-analysis.
    Int Immunopharmacol. 2019;67:378-385.
    Abstract    

    Abstract available

  45. SUN P, Wu T, Sun X, Cui Z, et al
    KMT2D inhibits the growth and metastasis of bladder Cancer cells by maintaining the tumor suppressor genes.
    Biomed Pharmacother. 2019;115:108924.
    Abstract    

    Abstract available

  46. AKAND M, Muilwijk T, Raskin Y, De Vrieze M, et al
    Quality Control Indicators for Transurethral Resection of Non-Muscle-Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2019 Apr 19. pii: S1558-7673(19)30140.
    Abstract    

    Abstract available

  47. AGREDA CASTANEDA F, Raventos Busquets CX, Morote Robles J
    Urinary markers in the surveillance of non-muscle invasive bladder cancer. A literature review.
    Actas Urol Esp. 2019 May 13. pii: S0210-4806(19)30041.
    Abstract    

    Abstract available

  48. ALMEIDA TC, Guerra CCC, Assis BLG, Soares RDOA, et al
    Antiproliferative and toxicogenomic effects of resveratrol in bladder cancer cells with different TP53 status.
    Environ Mol Mutagen. 2019 May 16. doi: 10.1002/em.22297.
    Abstract    

    Abstract available

  49. SHEN T, Yang L, Zhang Z, Yu J, et al
    KIF20A Affects the Prognosis of Bladder Cancer by Promoting the Proliferation and Metastasis of Bladder Cancer Cells.
    Dis Markers. 2019;2019:4863182.
    Abstract    

    Abstract available

  50. WASHINGTON SL, Neuhaus J, Meng MV, Porten SP, et al
    Social Determinants of Appropriate Treatment for Muscle-Invasive Bladder Cancer.
    Cancer Epidemiol Biomarkers Prev. 2019 May 15. pii: 1055-9965.EPI-18-1280.
    Abstract    

    Abstract available

  51. BOLENZ C, Hautmann RE
    [Surgical treatment of bladder cancer: advances made in the past 50 years].
    Aktuelle Urol. 2019 May 15. doi: 10.1055/a-0884-2792.
    Abstract    

    Abstract available

  52. ZHU Z, Wang X, Wang J, Wang S, et al
    Preoperative predictors of early death risk in bladder cancer patients treated with robot-assisted radical cystectomy.
    Cancer Med. 2019 May 15. doi: 10.1002/cam4.2237.
    Abstract    

    Abstract available

  53. LEE YH, Tuyet PT
    Synthesis and biological evaluation of quercetin-zinc (II) complex for anti-cancer and anti-metastasis of human bladder cancer cells.
    In Vitro Cell Dev Biol Anim. 2019 May 14. pii: 10.1007/s11626-019-00363.
    Abstract    

    Abstract available

  54. MA JY, Hu G, Liu Q
    Prognostic Significance of the Lymphocyte-to-Monocyte Ratio in Bladder Cancer Undergoing Radical Cystectomy: A Meta-Analysis of 5638 Individuals.
    Dis Markers. 2019;2019:7593560.
    Abstract    

    Abstract available

  55. XU Y, Kim YH, Jeong P, Piao XM, et al
    Urinary Cell-Free DNA IQGAP3/BMP4 Ratio as a Prognostic Marker for Non-Muscle-Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2019 Apr 9. pii: S1558-7673(19)30012.
    Abstract    

    Abstract available

  56. GARRY EM, Buse JB, Gokhale M, Lund JL, et al
    Study Design Choices for Evaluating Comparative Safety of Diabetic Medications: An Evaluation of Pioglitazone and Bladder Cancer Risk Among Older US Adults with Type-2 Diabetes.
    Diabetes Obes Metab. 2019 May 14. doi: 10.1111/dom.13774.
    Abstract    

    Abstract available

  57. TYRITZIS SI, Gaya JM, Wallestedt-Lantz A, Pini G, et al
    Current role of robotic bladder cancer surgery.
    Minerva Urol Nefrol. 2019 May 7. pii: S0393-2249.19.03435.
    Abstract    

    Abstract available

  58. WU YJ, Su TR, Dai GF, Su JH, et al
    Flaccidoxide-13-Acetate-Induced Apoptosis in Human Bladder Cancer Cells is through Activation of p38/JNK, Mitochondrial Dysfunction, and Endoplasmic Reticulum Stress Regulated Pathway.
    Mar Drugs. 2019;17.
    Abstract    

    Abstract available

  59. LUO F, Ma C, Wu J, Li J, et al
    Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Nonmuscle-Invasive Bladder Cancer Treated with GreenLight Laser Vaporization.
    Photobiomodul Photomed Laser Surg. 2019;37:312-317.
    Abstract    

    Abstract available

  60. LI J, Wang F, Gao H, Huang S, et al
    ALDOLASE A regulates invasion of bladder cancer cells via E-cadherin-EGFR signaling.
    J Cell Biochem. 2019 May 13. doi: 10.1002/jcb.28642.
    Abstract    

    Abstract available

  61. SORIA F, Mosca A, Gontero P
    Drug strategies for bladder cancer in the elderly: is there promise for the future?
    Expert Opin Pharmacother. 2019 May 13:1-10. doi: 10.1080/14656566.2019.1615055.
    Abstract    

    Abstract available

  62. MELEIS L, Moore R, Inman BA, Harrison MR, et al
    Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer.
    J Oncol Pharm Pract. 2019 May 12:1078155219845434. doi: 10.1177/1078155219845434
    Abstract    

    Abstract available

  63. CHEN J, Miranda G, Cai J, Daneshmand S, et al
    Preoperative chemotherapy for prostatic stromal invasive urothelial bladder cancer: comparison of oncological outcomes of male patients with cT4a disease undergoing radical cystectomy with or without preoperative chemotherapy.
    Scand J Urol. 2019 May 13:1-6. doi: 10.1080/21681805.2019.1613445.
    Abstract    

    Abstract available

  64. XIE Y, Li P, Gao Y, Gu L, et al
    Correction: Reduced E-cadherin expression is correlated with poor prognosis in patients with bladder cancer: a systematic review and meta-analysis.
    Oncotarget. 2019;10:2657.
    Abstract    

    Abstract available

  65. PANDEY S, Garg RK, Malhotra HS, Uniyal R, et al
    Atypical frontal lobe seizure as the first manifestation of gall-bladder cancer: a case report.
    BMC Neurol. 2019;19:95.
    Abstract    

    Abstract available

  66. LONG X, Xiong W, Zeng X, Qi L, et al
    Cancer-associated fibroblasts promote cisplatin resistance in bladder cancer cells by increasing IGF-1/ERbeta/Bcl-2 signalling.
    Cell Death Dis. 2019;10:375.
    Abstract    

    Abstract available

  67. WESTHOFF E, Kampman E, Aben KK, Hendriks IG, et al
    Low awareness, adherence, and practice but positive attitudes regarding lifestyle recommendations among non-muscle-invasive bladder cancer patients.
    Urol Oncol. 2019 May 8. pii: S1078-1439(19)30149.
    Abstract    

    Abstract available

  68. NAZEMI A, Ghodoussipour S, Pearce S, Bhanvadia S, et al
    Socioeconomic and insurance status are independent prognostic indicators of higher disease stage and worse prognosis in bladder cancer.
    Urol Oncol. 2019 May 8. pii: S1078-1439(19)30154.
    Abstract    

    Abstract available

  69. HAYASHI Y, Fujita K, Matsuzaki K, Matsushita M, et al
    Diagnostic potential of TERT promoter and FGFR3 mutations in urinary cell-free DNA in upper tract urothelial carcinoma.
    Cancer Sci. 2019;110:1771-1779.
    Abstract    

    Abstract available

  70. KOGUCHI D, Matsumoto K, Ikeda M, Taoka Y, et al
    Histologic variants associated with biological aggressiveness and poor prognosis in patients treated with radical cystectomy.
    Jpn J Clin Oncol. 2019;49:373-378.
    Abstract    

    Abstract available

  71. ANWAR T, Malm-Buatsi E
    Propranolol as an effective therapy for infantile haemangioma of the urinary bladder.
    BMJ Case Rep. 2019;12.
    Abstract    

    Abstract available

  72. JUNG M, Lee JH, Kim B, Park JH, et al
    Transcriptional Analysis of Immunohistochemically Defined Subgroups of Non-Muscle-Invasive Papillary High-Grade Upper Tract Urothelial Carcinoma.
    Int J Mol Sci. 2019;20.
    Abstract    

    Abstract available

  73. PEREIRA R, McGeorge S, Perera M, Vela I, et al
    Urachal Mucinous Cystadenocarcinoma.
    BMJ Case Rep. 2019;12.
    Abstract    

    Abstract available

  74. BAGHDADI A, Hussein AA, Ahmed Y, Cavuoto LA, et al
    A computer vision technique for automated assessment of surgical performance using surgeons' console-feed videos.
    Int J Comput Assist Radiol Surg. 2019;14:697-707.
    Abstract    

    Abstract available

  75. LI JR, Chiu KY, Ou YC, Wang SS, et al
    Alteration in serum concentrations of FGF19, FGF21, and FGF23 in patients with urothelial carcinoma.
    Biofactors. 2019;45:62-68.
    Abstract    

    Abstract available

  76. FISCHER-VALUCK BW, Michalski JM, Mitra N, Christodouleas JP, et al
    Effectiveness of postoperative radiotherapy after radical cystectomy for locally advanced bladder cancer.
    Cancer Med. 2019 May 22. doi: 10.1002/cam4.2102.
    Abstract    

    Abstract available

  77. GIL D, Zarzycka M, Dulinska-Litewka J, Ciolczyk-Wierzbicka D, et al
    Dihydrotestosterone increases the risk of bladder cancer in men.
    Hum Cell. 2019 May 22. pii: 10.1007/s13577-019-00255.
    Abstract    

    Abstract available

  78. WANG C, Zhu X, Li A, Yang S, et al
    S100A16 regulated by Snail promotes the chemoresistance of nonmuscle invasive bladder cancer through the AKT/Bcl-2 pathway.
    Cancer Manag Res. 2019;11:2449-2456.
    Abstract    

    Abstract available

  79. FLAIG TW
    NCCN Guidelines Updates: Management of Muscle-Invasive Bladder Cancer.
    J Natl Compr Canc Netw. 2019;17.
    Abstract    

    Abstract available

  80. LI B, Xie D, Zhang H
    Long non-coding RNA GHET1 contributes to chemotherapeutic resistance to Gemcitabine in bladder cancer.
    Cancer Chemother Pharmacol. 2019 May 21. pii: 10.1007/s00280-019-03873.
    Abstract    

    Abstract available

  81. ZHAO X, Wang D, Ding Y, Zhou J, et al
    lncRNA ZEB1-AS1 promotes migration and metastasis of bladder cancer cells by post-transcriptional activation of ZEB1.
    Int J Mol Med. 2019 May 8. doi: 10.3892/ijmm.2019.4187.
    Abstract    

    Abstract available

  82. NAKAHARA K, Yamasaki K, Nagai T, Fujii M, et al
    Expression of protease activating receptor-2 (PAR-2) is positively correlated with the recurrence of non-muscle invasive bladder cancer: an immunohistochemical analysis.
    Res Rep Urol. 2019;11:97-104.
    Abstract    

    Abstract available

  83. MAURYA N, Singh R, Goel A, Singhai A, et al
    Clinicohistopathological implications of phosphoserine 9 glycogen synthase kinase-3beta/ beta-catenin in urinary bladder cancer patients.
    World J Clin Oncol. 2019;10:166-182.
    Abstract    

    Abstract available

  84. SHI MJ, Meng XY, Wu QJ, Zhou XH, et al
    High CD3D/CD4 ratio predicts better survival in muscle-invasive bladder cancer.
    Cancer Manag Res. 2019;11:2987-2995.
    Abstract    

    Abstract available

  85. HAN C, Ma T, Lei D, Xie S, et al
    Effect of ultrasound-guided proximal and distal approach for obturator nerve block in transurethral resection of bladder cancer under spinal anesthesia.
    Cancer Manag Res. 2019;11:2499-2505.
    Abstract    

    Abstract available

  86. XU X, Zhang G, He L, Zhu Y, et al
    Clinicopathological impacts of c-Met overexpression in bladder cancer: evidence from 1,336 cases.
    Onco Targets Ther. 2019;12:2695-2702.
    Abstract    

    Abstract available

  87. KROCHMAL M, van Kessel KEM, Zwarthoff EC, Belczacka I, et al
    Urinary peptide panel for prognostic assessment of bladder cancer relapse.
    Sci Rep. 2019;9:7635.
    Abstract    

    Abstract available

  88. SANCAR F
    Precision Approach to Bladder Cancer.
    JAMA. 2019;321:1862.
    Abstract    



  89. KONG J, Diao X, Diao F, Fan X, et al
    Causes of death in long-term bladder cancer survivors: A population-based study.
    Asia Pac J Clin Oncol. 2019 May 20. doi: 10.1111/ajco.13156.
    Abstract    

    Abstract available

  90. WAINGANKAR N, Jia R, Marqueen KE, Audenet F, et al
    The impact of pathologic response to neoadjuvant chemotherapy on conditional survival among patients with muscle-invasive bladder cancer.
    Urol Oncol. 2019 May 18. pii: S1078-1439(19)30160.
    Abstract    

    Abstract available

  91. BURDEN S, Billson HA, Lal S, Owen KA, et al
    Perioperative nutrition for the treatment of bladder cancer by radical cystectomy.
    Cochrane Database Syst Rev. 2019;5:CD010127.
    Abstract    

    Abstract available

  92. HUANG J, Shiao SL, Furuya H, Rosser CJ, et al
    Immunogenomic Analysis of Exceptional Responder to ALT-803 (IL-15 Analogue) in BCG Unresponsive Nonmuscle Invasive Bladder Cancer: A Case Series and Review of the Literature.
    J Immunother. 2019 May 15. doi: 10.1097/CJI.0000000000000269.
    Abstract    

    Abstract available

  93. WU SC, Kwon D, Jue JS, Chen FV, et al
    Androgen Suppression Therapy Is Associated with Lower Recurrence of Non-muscle-invasive Bladder Cancer.
    Eur Urol Focus. 2019 May 15. pii: S2405-4569(19)30141.
    Abstract    

    Abstract available

  94. SANKIN A, Chand D, Schoenberg M, Zang X, et al
    Human urothelial bladder cancer generates a clonal immune response: The results of T-cell receptor sequencing.
    Urol Oncol. 2019 May 15. pii: S1078-1439(19)30144.
    Abstract    

    Abstract available

  95. SONG D, Powles T, Shi L, Zhang L, et al
    Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.
    J Pathol. 2019 May 18. doi: 10.1002/path.5306.
    Abstract    

    Abstract available

  96. STANIK M, Poprach A, Zapletalova M, Krejci D, et al
    Comparison of Different Treatment Modalities Outcomes in Clinically Node-positive Bladder Cancer: Analysis of a Population-based Cancer Registry.
    Clin Genitourin Cancer. 2019 Apr 16. pii: S1558-7673(19)30133.
    Abstract    

    Abstract available

  97. DONG W, Bi J, Liu H, Yan D, et al
    Circular RNA ACVR2A suppresses bladder cancer cells proliferation and metastasis through miR-626/EYA4 axis.
    Mol Cancer. 2019;18:95.
    Abstract    

    Abstract available

  98. LORAS A, Suarez-Cabrera C, Martinez-Bisbal MC, Quintas G, et al
    Integrative Metabolomic and Transcriptomic Analysis for the Study of Bladder Cancer.
    Cancers (Basel). 2019;11.
    Abstract    

    Abstract available

  99. BERMEJO LM, Lopez-Plaza B, Santurino C, Cavero-Redondo I, et al
    Milk and Dairy Product Consumption and Bladder Cancer Risk: A Systematic Review and Meta-Analysis of Observational Studies.
    Adv Nutr. 2019;10.
    Abstract    

    Abstract available

  100. FLAUS A, Longo MG, Dematons M, Granjon D, et al
    18F-FDG PET/CT in Urachal Abscess.
    Clin Nucl Med. 2019 Mar 1. doi: 10.1097/RLU.0000000000002524.
    Abstract    

    Abstract available

  101. BILLGER M, Kirk J, Chang J, Bedard A, et al
    A study in a rat initiation-promotion bladder tumour model demonstrated no promoter/progressor potential of dapagliflozin.
    Regul Toxicol Pharmacol. 2019;103:166-173.
    Abstract    

    Abstract available

  102. JOHANSSON VR, von Vogelsang AC
    Patient-reported extremity symptoms after robot-assisted laparoscopic cystectomy.
    J Clin Nurs. 2019;28.
    Abstract    

    Abstract available

  103. EL RASSY E, Assi T, Bakouny Z, Pavlidis N, et al
    Beyond first-line systemic treatment for metastatic urothelial carcinoma of the bladder.
    Clin Transl Oncol. 2019;21:280-288.
    Abstract    

    Abstract available

  104. NAKAMURA Y, Miyata Y, Takehara K, Asai A, et al
    The Pathological Significance and Prognostic Roles of Thrombospondin-1, and -2, and 4N1K-peptide in Bladder Cancer.
    Anticancer Res. 2019;39:2317-2324.
    Abstract    

    Abstract available

  105. SEILER R, Wyatt AW, Black PC
    Molecular landscape of muscle-invasive bladder cancer: Patient age matter?
    BJU Int. 2019 May 9. doi: 10.1111/bju.14802.
    Abstract    

    Abstract available

  106. WARD DG, Gordon NS, Boucher RH, Pirrie SJ, et al
    Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification.
    BJU Int. 2019 May 11. doi: 10.1111/bju.14808.
    Abstract    

    Abstract available

  107. YU EY, Nekeman D, Aaronson NK, Billingham LJ, et al
    Health-Related Quality of Life in Bladder Cancer Patients around the Time of Diagnosis.
    BJU Int. 2019 May 11. doi: 10.1111/bju.14804.
    Abstract    

    Abstract available

  108. MCCLINTOCK TR
    Palliative care in patients with bladder cancer: an opportunity for value improvement?
    BJU Int. 2019;123:913-914.
    Abstract    



  109. SCHROECK FR, Lynch KE, Li Z, MacKenzie TA, et al
    The impact of frequent cystoscopy on surgical care and cancer outcomes among patients with low-risk, non-muscle-invasive bladder cancer.
    Cancer. 2019 May 23. doi: 10.1002/cncr.32185.
    Abstract    

    Abstract available

  110. DIJKSTRA S, Wijburg CJ
    Re: Bernard H. Bochner, Guido Dalbagni, Karim H. Marzouk, et al. Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outcomes. Eur Urol 2018;74:465-71: Can the Pattern of Cancer Recurrence T
    Eur Urol. 2019;75:e137.
    Abstract    



  111. BOCHNER BH, Dalbagni G
    Reply to Siebren Dijkstra and Carl J. Wijburg's Letter to the Editor re: Bernard H. Bochner, Guido Dalbagni, Karim H. Marzouk, et al. Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outc
    Eur Urol. 2019;75:e138-e139.
    Abstract    



  112. GSCHWEND JE, Heck M
    Reply to Satoru Taguchi, Tohru Nakagawa, and Hiroshi Fukuhara's Letter to the Editor re: Jurgen E. Gschwend, Matthias M. Heck, Jan Lehmann, et al. Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy:
    Eur Urol. 2019 May 2. pii: S0302-2838(19)30346.
    Abstract    



  113. LI R, Spiess PE, Gilbert SM, Necchi A, et al
    Reply to Yubo Yang, Xin Wei, and Ping Han's Letter to the Editor re: Roger Li, Philippe E. Spiess, Scott M. Gilbert, Andrea Necchi. Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.101
    Eur Urol. 2019 May 2. pii: S0302-2838(19)30344.
    Abstract    



  114. YANG Y, Wei X, Han P
    Re: Roger Li, Philippe E. Spiess, Scott M. Gilbert, Andrea Necchi. Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.02.027.
    Eur Urol. 2019 May 1. pii: S0302-2838(19)30343.
    Abstract    



  115. TAGUCHI S, Nakagawa T, Fukuhara H
    Re: Jurgen E. Gschwend, Matthias M. Heck, Jan Lehmann, et al. Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial. Eur Urol 2019;75:604-11.
    Eur Urol. 2019 May 1. pii: S0302-2838(19)30345.
    Abstract    



  116. CAO L, Yang Z, Wang B
    Re: F. Johannes P. van Valenberg, Andrew M. Hiar, Ellen Wallace, et al. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer. Eur Urol. 2019; 75,5: 853-860.
    Eur Urol. 2019 May 10. pii: S0302-2838(19)30364.
    Abstract    



  117. VARMA M, Delahunt B, van der Kwast T
    Grading Noninvasive Bladder Cancer: World Health Organisation 1973 or 2004 May Be the Wrong Question.
    Eur Urol. 2019 May 10. pii: S0302-2838(19)30362.
    Abstract    

    Abstract available

  118. BESSA A, Maclennan S, Enting D, Bryan R, et al
    Reply to Jon Mikel Inarritu, Daniele Castellani, and Jeremy Y.C. Teoh's Letter to the Editor re: Agustina Bessa, Steven Maclennan, Deborah Enting, et al. Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Usi
    Eur Urol. 2019 May 17. pii: S0302-2838(19)30379.
    Abstract    



  119. INARRITU JM, Castellani D, Teoh JYC
    Re: Agustina Bessa, Steven Maclennan, Deborah Enting, et al. Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method. Eur Urol. In press. https://doi.org/10.1016/j.eururo.
    Eur Urol. 2019 May 15. pii: S0302-2838(19)30378.
    Abstract    



  120. LAAKSONEN MA, MacInnis RJ, Canfell K, Giles GG, et al
    The future burden of kidney and bladder cancers preventable by behaviour modification in Australia: a pooled cohort study.
    Int J Cancer. 2019 May 20. doi: 10.1002/ijc.32420.
    Abstract    

    Abstract available

  121. HORI S, Miyake M, Onishi S, Morizawa Y, et al
    Evaluation of pro and antitumor effects induced by three colonystimulating factors, GCSF, GMCSF and MCSF, in bladder cancer cells: Is GCSF a friend of bladder cancer cells?
    Int J Oncol. 2019;54:2237-2249.
    Abstract    

    Abstract available

  122. MENG MV, Gschwend JE, Shore N, Grossfeld GD, et al
    Emerging Immunotherapy Options for BCG-unresponsive Non-muscle-invasive Bladder Cancer.
    J Urol. 2019 May 1:101097JU0000000000000297. doi: 10.1097/JU.0000000000000297.
    Abstract    

    Abstract available

  123. CHANG SS
    Re: Discrepancies in Staging, Treatment, and Delays to Treatment May Explain Disparities in Bladder Cancer Outcomes: An Update from the National Cancer Data Base (2004-2013).
    J Urol. 2019 May 8:10109701JU000055962335906.
    Abstract    



  124. CHANG SS
    Re: Characterization of Late Recurrence after Radical Cystectomy in a Large Multicenter Cohort of Bladder Cancer Patients.
    J Urol. 2019 May 8:10109701JU00005596222828385.
    Abstract    



  125. CHANG SS
    Re: Extended versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial.
    J Urol. 2019 May 8:101097JU0000000000000332. doi: 10.1097/JU.0000000000000332.
    Abstract    



  126. WOLDU SL
    Editorial Comment.
    J Urol. 2019;201:901.
    Abstract    



  127. LOTAN Y, Inman BA, Davis LG, Kassouf W, et al
    Evaluation of the UroVysion Test to Predict Recurrence and/or Progression of Disease After BCG for Primary High Grade Non-Muscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial.
    J Urol. 2019 May 23:101097JU0000000000000355. doi: 10.1097/JU.0000000000000355.
    Abstract    

    Abstract available

  128. MORERA DS, Lahorewala SS, Belew D, Ghosh S, et al
    Clinical parameters outperform molecular subtypes for predicting outcome in bladder cancer: Results from multiple cohorts including TCGA.
    J Urol. 2019 May 21:101097JU0000000000000351. doi: 10.1097/JU.0000000000000351.
    Abstract    

    Abstract available

  129. PALMBOS PL, Wang Y, Bankhead Iii A, Kelleher AJ, et al
    ATDC mediates a TP63-regulated basal cancer invasive program.
    Oncogene. 2019;38:3340-3354.
    Abstract    

    Abstract available

  130. HERR H
    Preventable Cancer Deaths associated with Bladder-Preservation for Muscle Invasive Bladder Cancer.
    Urology. 2019 May 6. pii: S0090-4295(19)30425.
    Abstract    



  131. BAT T, Buck DA, Nathan R, Cinquino J, et al
    Advanced Bladder Cancer Rechallenged With an Immune Checkpoint Inhibitor: A Case Report.
    Urology. 2019 May 3. pii: S0090-4295(19)30421.
    Abstract    



  132. ROYCE TJ, Efstathiou JA
    Editorial comment.
    Urology. 2019;124:189-190.
    Abstract    



  133. BANDARI J, Maganty A, Davies BJ
    Editorial Comment.
    Urology. 2019;124:125-126.
    Abstract    



  134. HONG P, Ding GP, Hao H, Yang KL, et al
    Laparoscopic Radical Cystectomy With Extracorporeal Neobladder: Our Initial Experience.
    Urology. 2019;124:286-291.
    Abstract    

    Abstract available

  135. RAGUE JT, Lee RS
    Management of High-grade, Nonmuscle Invasive Urothelial Carcinoma in a Prepubertal Patient With TURBT and Intravesical BCG.
    Urology. 2019;124:257-259.
    Abstract    

    Abstract available

  136. HERR H, Donat M
    Reduced Recurrence of Low-grade Papillary Bladder Tumors Associated With Asymptomatic Bacteriuria.
    Urology. 2019;124:179-182.
    Abstract    

    Abstract available

  137. HOARE D, Kiddoo D, Stryker T
    An Antenatally Detected Pure Malignant Rhabdoid Tumor of the Bladder.
    Urology. 2019;123:221-223.
    Abstract    

    Abstract available

  138. SYU SH, Chan KS, Hsiao CH, Chen WY, et al
    A Large Urinary Bladder Hemangioma Mimicking Urachal Cancer: A Case Report and Literature Review.
    Urology. 2019;123:224-226.
    Abstract    

    Abstract available

  139. KAYE DR, Ye Z, Li J, Herrel LA, et al
    The Stability of Physician-Specific Episode Costs for Urologic Cancer Surgery: Implications for Urologists Under the Merit-Based Incentive Program.
    Urology. 2019;123:114-119.
    Abstract    

    Abstract available

  140. WETTSTEIN MS, Rooprai JK, Pazhepurackel C, Wallis CJD, et al
    Systematic review and meta-analysis on trimodal therapy versus radical cystectomy for muscle-invasive bladder cancer: Does the current quality of evidence justify definitive conclusions?
    PLoS One. 2019;14:e0216255.
    Abstract    

    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;